That already tops Lilly's full 2025 capital allocation of $32.3 billion, a sign of how much its obesity drug cash is fueling spending.
Recap by typeshit. Post by Kyle LaHucik on X.
Tara Wider has spent about five years posting on holistic beauty and women's wellness, building a following of women her age on social media.
Brown says diet and exercise still matter, but argues that shaming people for treating obesity with medication has never made anyone healthier.
A short share on growing GLP-1 use in the US, with no figures or sources attached. Thin on detail beyond the headline itself.
A new survey covered by Chain Store Age tracks how GLP-1 users are shifting their food spending from restaurants toward grocery stores.
17:15
Sandy Gibson shares a personal update two months into taking tirzepatide and weighs whether it is doing its job.
The multi-year trial, Oura's first, will test whether ring data on sleep, heart rate and activity lines up with weight loss, HbA1c and staying on treatment.
Loading…